Park Jimin, Joo Young Su, Nam Bo Young, Kim Gyuri, Park Jung Tak, Yoo Tae-Hyun, Kang Shin-Wook, Han Seung Hyeok
Department of Internal Medicine, College of Medicine, Institute of Kidney Disease Research, Yonsei University, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
Severance Biomedical Science Institute, College of Medicine, Yonsei University, Seoul, Korea.
Mol Med. 2025 Jul 25;31(1):266. doi: 10.1186/s10020-025-01320-4.
Pyruvate kinase isoform M2 (PKM2) activation has been suggested as a potential protective mechanism against kidney injury by improving mitochondrial dysfunction and anaerobic glycolysis. However, the underlying molecular mechanisms are unclear. Herein, we have demonstrated that PKM2 activation alleviates HIF-1α-mediated suppression of PGC-1α in diabetic kidney disease (DKD) models.
In animal DKD study, db/db mice were intraperitoneally injected with TEPP-46, a PKM2 activator. In vitro, primary cultured renal tubular epithelial cells (RTECs) from C57BL/6 mice were exposed to high glucose (HG) conditions with and without TEPP-46. The interaction between HIF-1α and PGC-1α was investigated using HIF-1α overexpression and suppression.
Our findings in db/db mice kidneys unveiled a reduced PKM2 activation, aberrant glycolysis, impaired fatty acid oxidation, and decreased mitochondrial mass, integrity, and function under diabetic conditions. These changes were accompanied by increased HIF-1α and decreased PGC-1α levels. Furthermore, diabetic kidney exhibited increased fibrosis and apoptosis markers. Notably, direct PKM2 activation by TEPP-46 treatment counteracted the perturbed energy metabolism, restored mitochondrial function, and reduced cell death. Similar effects were also observed in HG-treated RTECs upon TEPP-46 intervention. Mechanistically, our chromatin immunoprecipitation assay revealed that HIF-1α directly bound to the regulatory region of the Ppargc1a promoter, and this interaction was inversely dependent on PKM2 activation. Moreover, Hif1ɑ overexpression suppressed Ppargc1a and triggered aberrant energy metabolism, mitochondrial dysfunction, and apoptosis. These changes were reversed by HIF-1α suppression.
Our study highlights the role of PKM2 activation in restoring impaired mitochondrial metabolism and function by modulating HIF-1α and PGC-1α interactions in DKD.
丙酮酸激酶同工酶M2(PKM2)激活被认为是一种通过改善线粒体功能障碍和无氧糖酵解来对抗肾损伤的潜在保护机制。然而,其潜在的分子机制尚不清楚。在此,我们证明了PKM2激活可减轻糖尿病肾病(DKD)模型中HIF-1α介导的对PGC-1α的抑制作用。
在动物DKD研究中,给db/db小鼠腹腔注射PKM2激活剂TEPP-46。在体外,将来自C57BL/6小鼠的原代培养肾小管上皮细胞(RTECs)置于有或无TEPP-46的高糖(HG)条件下。使用HIF-1α过表达和抑制来研究HIF-1α与PGC-1α之间的相互作用。
我们在db/db小鼠肾脏中的研究结果表明,在糖尿病条件下,PKM2激活减少,糖酵解异常,脂肪酸氧化受损,线粒体质量、完整性和功能下降。这些变化伴随着HIF-1α增加和PGC-1α水平降低。此外,糖尿病肾脏中纤维化和凋亡标志物增加。值得注意的是,TEPP-46治疗直接激活PKM2可抵消能量代谢紊乱,恢复线粒体功能,并减少细胞死亡。在TEPP-46干预后,HG处理的RTECs中也观察到类似效果。从机制上讲,我们的染色质免疫沉淀试验表明,HIF-1α直接与Ppargc1a启动子的调控区域结合,这种相互作用与PKM2激活呈负相关。此外,Hif1ɑ过表达抑制Ppargc1a并引发异常能量代谢、线粒体功能障碍和凋亡。这些变化通过抑制HIF-1α得以逆转。
我们的研究强调了PKM2激活在通过调节DKD中HIF-1α和PGC-1α相互作用来恢复受损线粒体代谢和功能方面的作用。